Oct 21, 2020
Bernard Gilly PhD, CEO and Co-Founder, GenSight Biologics talks about the innovative gene therapy treatments GenSight is developing to fight blinding diseases. Bernard sheds light on treating Leber Hereditary Optic Neuropathy (LHON), a mitochondrial rare disease as well as retinitis pigmentosa (RP). Their goal is to change the lives of patients who are either losing their sight or have lost their sight because of a neurodegenerative condition in their retina.
@GenSightBio #blindness #LHON #RP #retinitispigmentosa #augmentedvision